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Abstract
Over the past decade, interest has increased in the use of exogenous stem cells to optimize lung repair and serve as carriers of a
therapeutic gene for genetic airway disease such as cystic fibrosis. We investigated the survival and the engraftment of exogenous
stem cells after intratracheal injection, in a murine model of acute epithelial airway injury already used in gene therapy experiments
on cystic fibrosis. Embryonic stem cells and mesenchymal stem cells were intratracheally injected 24hr after 2  polidocanol%
administration, when epithelial airway injury was maximal. Stem cells were transfected with reporter genes immediately prior to
administration. Reporter gene expression was analyzed in trachea-lungs and bronchoalveolar lavages using non-fluorescent,
quantitative and sensitive methods. ELISA quantitative results showed that 0.4 to 5.5  stem cells survived in the injured airway.%
Importantly, no stem cells survived in healthy airway or in the epithelial lining fluid. Using X-Gal staining, transduced mesenchymal
stem cells were detected in injured trachea and bronchi lumen. When the epithelium was spontaneously regenerated, the in vivo 
amount of engrafted mesenchymal stem cells from cell line decreased dramatically. No stem cells from primary culture were located
within lungs at 7 days. This study demonstrated the feasibility of the intratracheal cell delivery for airway diseases with acute
epithelial injury.
MESH Keywords Analysis of Variance ; Animals ; Bronchoalveolar Lavage ; DNA Primers ; genetics ; Embryonic Stem Cells ; transplantation ; Enzyme-Linked
Immunosorbent Assay ; Galactosides ; Genetic Engineering ; methods ; Genetic Vectors ; Indoles ; Male ; Mesenchymal Stem Cell Transplantation ; methods ; Mice ; 
Respiratory Tract Diseases ; therapy ; Tissue Therapy ; methods ; Trachea ; cytology ; Transfection ; beta-Galactosidase
Introduction
Respiratory diseases remain one of the main causes of morbidity and mortality in the world. Interest has increased as to the possibility
of optimizing the repair of the lung with the use of stem cells (SCs). In particular, combining SC ability to engraft into damaged lungs and
their ability to serve as carriers of a therapeutic gene has a great potential for pulmonary fibrosis ( ) and for geneticLoebinger 2008 et al., 
airway disease such as cystic fibrosis. This developing therapeutic approach has been stimulated by early reports demonstrating that both
embryonic stem cells and SCs derived from adult bone marrow, including mesenchymal stem cells, can differentiate into respiratory cells 
, thus acquiring phenotypic and functional markers of airway and alveolar epithelial cells ( ; ; in vitro Coraux 2005 et al., Wang 2005 et al., 
). Systemic administration of adult SCs from bone marrow in mice after total-body irradiation ( ; Rippon 2006 et al., Pereira 1995 et al., 
; ) and/or pollutant-reagent treatment have been reported recently ( ; Loebinger 2008 et al., Sueblinvong 2008 et al., Beckett 2005 et al., 
; ; ; ; ) and showed that theMacPherson 2006 et al., Mei 2007 et al., Serikov 2007 et al., Xu 2007 et al., Loebinger 2008 et al., 
administered SCs were mainly engrafted in alveolar spaces ( ; ; ; Pereira 1995 et al., Beckett 2005 et al., Mei 2007 et al., Serikov et al., 
; ; ; ) and sometimes in conducting airway ( ; 2007 Xu 2007 et al., Loebinger 2008 et al., Sueblinvong 2008 et al., Pereira 1995 et al., 
; ; ; ; ). The SC differentiation asKrause 2001 et al., MacPherson 2005 et al., Loi 2006 et al., MacPherson 2006 et al., Serikov 2007 et al., 
pneumocytes (I or II) or airway epithelial cells was mostly evaluated using different fluorescence techniques. Reported engraftment rates
of adult bone marrow SC-derived cells ranged from 0  ( ) up to 20  ( ) in the lungs, and from 0.025% Wagers 2002 et al., % Krause 2001 et al., 
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 ( ) up to 4  ( ) in conducting airway. These discrepancies have been partly attributed to the different% Loi 2006 et al., % Krause 2001 et al., 
fluorescence techniques used to detect the donor-derived epithelial cells, leading to significant artifacts ( ).Loebinger 2008 et al., 
Importantly, lung SC engraftment is currently estimated to be between 0.01  and 0.1  ( ; ). Despite this% % Krause 2005 Bruscia 2006 et al., 
low engraftment level, there is evidence that transplanted SC post-injury have some therapeutic effects ( ).Loebinger 2008 et al., 
In most of these studies, systemic administration of SCs required total-body irradiation of the recipient to promote SC bone marrow
engraftment, a difficult condition to apply in the clinical setting, especially in patients suffering from airway disease associated with
chronic infections such as cystic fibrosis. Alternatively, considering the advantages of the intratracheal route to target the airway and the
respiratory epithelium, more recent studies reported the intratracheal administration of adult SCs in reagent-injured lungs (Gupta et al., 
; ). Using fluorescent techniques SC engraftment was enhanced with the intratracheal route as compared to the2007 Wong 2007 et al., 
intravenous route ( ; ) but remained 5 10  ( ; ; Wong 2007 et al., Wong 2009 et al., – % Gupta 2007 et al., Wong 2007 et al., Wong 2009 et al., 
). The intratracheal route was also used for the administration of differentiated cells and showed both positive (Serrano-Mollar 2007 et al., 
) and negative results ( ; ). SC or differentiated cell engraftment levels in these studies were mostlyKuang 2005 et al., Gupta 2007 et al., 
assessed using fluorescence techniques, which could explain these conflicting results.
The aims of our study were to evaluate the survival and the engraftment of different types of exogenous SCs and differentiated cells
after intratracheal injection. We used a murine model presenting acute epithelial airway injury without total-body irradiation. This model
was developed for gene therapy experiments on cystic fibrosis and consisted in intranasal injection of polidocanol detergent (Parsons et al.,
). Quantification of cell survival rates and cell location within lungs were performed using ELISA, biochemical assay and PCR.1998 
Materials and methods
Animal model and intratracheal administration
Male, 8- to 10-week old Swiss mice were obtained from Janvier Laboratories (Le Genest St Isle, France). Animal experiments were
performed under the approval of the published by the U.S. National Institutes ofGuide for The Care and Use of Laboratory Animals 
Health (NIH Publication No. 85-23, revised 1996). Mice were anesthetized with an intraperitoneal injection of xylazine (15mg/kg) and
ketamine (70mg/kg), and placed supine. Briefly, intratracheal administration was performed using a 22-gauge catheter placed within an
intubation canula (Harvard Apparatus) that was removed immediately before injection. Airway injury was induced after anaesthesia by
intratracheal administration of 25 l of 2  polidocanol (PDOC: polyoxyethylene 9-lauryl ether, Sigma, ( ; μ % Borthwick 2001 et al., 
)) in phosphate-buffered saline (PBS) through the 22-gauge catheter. Cells (10 cells/25 l) or PBS wereMacPherson 2005 et al., 6 μ
intratracheally injected 24hr after PDOC administration using the same protocol. Mice were sacrificed by an intraperitoneal lethal injection
of nesdonal 24hr or 7 days after intratracheal administration.
Bronchoalveolar lavages
Bronchoalveolar lavages (BALs) were performed 24hr after CAT-transfected cell administration in healthy or injured airway. Mice
were anesthetized and thoracic cavity was opened by careful dissection. The trachea was exposed, and a small transverse incision
performed just below the level of the larynx. BAL was then performed using one dose of 1 ml of PBS, ensuring that both lungs inflated
during the lavage process and that there was no leakage of lavage fluid from the trachea. BAL fluid was centrifuged at 400 g for 5 min.
The supernatant was removed and stored at 80 C until ELISA. Cell pellet was suspended in lysis buffer and stored at 80 C until ELISA.− ° − °
Cell cultures
Undifferentiated mouse embryonic stem cells (ESCs, R1 cell line, ( )) were cultured in dishes coated with 0.1Nagy 1993 et al., %
gelatine (Sigma). The culture medium was composed of Dulbecco minimum essential medium with 4.5g/l glucose (DMEM, Invitrogen)
supplemented with 15  FCS (Invitrogen), 0.1  non essential amino acids (Invitrogen), 1mM sodium pyruvate (Invitrogen), 2mM% %
L-Glutamine (Invitrogen), 10 M mercaptoethanol (Sigma), penicillin/streptomycin (100U/ml and 100 g/ml respectively, Invitrogen)7 − β μ
and 2000U/ml of LIF (Sigma).
Undifferentiated murine mesenchymal stem cells (BMC9s, ( )) were cultured as previously described (Dennis and Caplan 1996 
) in alpha MEM medium with nucleosides (Invitrogen) supplemented with 10  FCS (Invitrogen), 2mMChateauvieux 2007 et al., %
L-Glutamine (Invitrogen), penicillin/streptomycin (100U/ml and 100 g/ml respectively, Invitrogen).μ
A human hepatocellular carcinoma cell line (Hep 3B2.1-7, ATCC number HB-8064), transformed African green monkey kidney
fibroblast cell line (COS-7, ATCC Number CRL-1651) and murine osteosarcoma cell line (mOS-J, ( )) were used forJoliat 2002 et al., 
control experiments. Cells were cultured in DMEM medium with 4.5 g/l glucose supplemented with 15  FCS, 2 mM L-Glutamine,%
penicillin/streptomycin (100U/ml and 100 g/ml respectively).μ
Primary culture of adult mesenchymal stem cells
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Total bone marrow was obtained from wild type adult male Swiss mice and male Rosa26 lacZ-mice (background C57Bl/6J x 129S2,
kindly provided by Dr M.F. Gardahaut, Nantes, France) by flushing femurs and tibias with culture medium. Cells were plated at a density
of 500 000 cells/cm in medium composed of alpha MEM with nucleosides supplemented with 10  FCS, 2 mM L-Glutamine,2 %
penicillin/streptomycin (100U/ml and 100 g/ml respectively) and 2ng/ml of human FGF2 (AbCys). The culture medium was changed atμ
day 3 to remove non-adherent cells and was subsequently replaced weekly. The cells were grown for 2 3 weeks until confluence.–
Adherent cells were then detached by 0.5  trypsin-EDTA and plated at a density of 10 000 cells/cm . Subsequent passages and seeding of% 2 
the cells were performed at a density of 5 000 cells/cm . From passage 8, MSC cultures were characterized by FACS analysis (FACS2 
Calibur Instrument, BD Biosciences, CellQuestPro Software) after incubation with anti-CD45-PE, anti-CD90-PE, anti-CD29-CyChrome,
anti-Sca1-PE, anti CD106-CyChrome (BD Biosciences) ( ).Dominici 2006 et al., 
In vitro cell transfection with CAT or GFP reporter genes and evaluation of gene transfer system efficacy
ESCs, BMC9s and differentiated cells were transfected with pCIK-CAT (4.7 Kb) and pEGFP-C1 (4.7 Kb) plasmids encoding for
Chloramphenicol AcetylTransferase (CAT) protein and GFP, using synthetic vectors just prior to intratracheal administration (Pitard et al.,
). DNA plasmids were complexed with ICAfectin  441 according to the manufacturer s instruction (In-Cell-Art, Nantes, France).2001 ® ’
After 2hr, transfection complexes were removed by changing growth medium and cells were lysed for dosages or kept in culture for 24hr,
7 days, or injected intratracheally as indicated above.
MSCs from Swiss mice were transfected with pCIK-CAT and pEGFP-C1 plasmids using nucleofection (Nucleofector Solution,
Amaxa Biosystem) just prior to intratracheal administration ( ). After 2hr, growth medium was changed and cells wereAluigi 2006 et al., 
lysed for dosages or kept in culture for 24hr, 7 days, or injected intratracheally as indicated above. The percentage of GFP-expressing cells
was evaluated 24hr after GFP nucleofection using FACS analysis.
The efficacy of gene transfer systems was evaluated using cytometry for GFP-expressing cells and ELISA for CAT-expressing cells.
The percentage of GFP-expressing cells was evaluated 24hr after GFP transfection using FACS analysis (FACS Calibur Instrument, BD
Biosciences, CellQuestPro Software). CAT protein quantity per stem cell at 24hr was then calculated using data: CAT proteinin vitro 
quantity in cell lysis buffer was divided by the cell number and by the percentage of GFP-expressing cells (obtained by FACS analysis).
Finally, this value was used to determine the minimum number of CAT-expressing stem cells required to be detected by ELISA or in vitro 
considering that CAT ELISA detection threshold was 50pg CAT protein (see below).in vivo 
In vitro stem cell transduction with nls-lacZ reporter gene
BMC9s were transduced with an amphotropic recombinant murine retrovirus vector containing the nls-LacZ reporter gene (LacZ gene
encoding  galactosidase ( gal) coupled to a nuclear localization signal (nls), kindly provided by Dr. N. Ferry, Nantes, France). Thisβ β
retrovirus vector was obtained from the human producer cell line TELCeB6AF7 derived from the Te671 cell line as described in (Aubert 
). 24hr recombinant retroviral supernatant was harvested from the confluent producer cell line and filtered through a 0.45 m2002 et al., μ
membrane. The titer of the gal supernatant, determined by endpoint dilution using Te671 target cells, was 2  10 transducingβ × 8 
particles/ml. After BMC9 transduction, retrovirus vector was removed by changing growth medium and cells were lysed for dosages or
kept in culture or injected intratracheally as indicated above.
To evaluate the percentage of gal-transduced BMC9s, cells were fixed in 4  paraformaldehyde, washed with PBS and incubated inβ %
5mM K4Fe(CN)6, 5mM K3Fe3(CN)6 and 2mM MgCl2 in PBS containing 0.5mg/ml X-Gal ( 5-bromo-4-chloro-3-indolyl-[ β
-D-galactopyranoside  dissolved in N,N-dimethylformamide at 20mg/ml before dilution into the reaction mixture, Sigma) for 2hr, at 37 C.] °
Cells were identified as positive for gal activity by blue nuclear staining after X-Gal reaction. The percentage of gal expressing cells β β in
was obtained by counting the number of nuclear-blue cells in a total of 200 cells.vitro 
MSCs from Swiss mice were transduced with a lentivirus vector containing the nls-lacZ reporter gene. The vector was derived from
pHR  LacZ ( ) in which a nls from the SV40 T Ag was cloned in frame 5  to the LacZ cDNA. The lentivirus vector’ Zufferey 1997 et al., ’
was produced on human embryonic kidney 293T cells as previously described ( ). After transduction with 50 MOISelig 1999 et al., 
(Multiplicity Of Infection), lentivirus vector was removed by changing growth medium and cells were lysed for dosages or kept in culture
or injected intratracheally as indicated above. The percentage of gal-transduced MSCs was evaluated by X-Gal staining andβ in vitro 
counting as described above.
Reporter gene assay and estimation of survival rate
CAT-transfected cells, BAL cells and BAL fluid, or whole frozen trachea-lungs were homogenized in reporter lysis buffer (Roche
Diagnostics) supplemented with protease inhibitors (Roche Diagnostics). After centrifugation at 10 000 rpm for 5min, CAT quantity was
measured in supernatant with a VICTOR multilabel counter (PerkinElmer), using a CAT enzyme-linked immunosorbent assay (ELISA)2 
kit according to the instructions of the supplier (Roche Diagnostics). Each sample was analyzed in duplicate. CAT detection threshold was
50pg. Protein content was measured with a bicinchoninic acid (BCA) protein assay kit (Pierce).
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To estimate cell survival rate 24hr after intratracheal administration, we first calculated CAT protein quantity per CAT-expressing cell,
using data: CAT quantity in cell lysis buffer was divided by the cell number and by the percentage of GFP-expressing cellsin vitro 
(obtained by FACS analysis). Finally, the total CAT protein quantity per animal was divided by this value, in order toin vivo in vitro 
estimate the number of CAT-expressing cells per animal and subsequently the cell survival rate.
BMC9s and Rosa26 MSCs or whole frozen murine trachea-lungs were homogenized in 1ml reporter lysis buffer (Roche Diagnostics)
supplemented with a protease inhibitor cocktail (Roche Diagnostics). After centrifugation at 10 000 rpm for 5min, gal activity wasβ
determined by enzymatic fluorimetric assay using 4MUG (4-methylumbelliferyl- -D-galactoside, Sigma) as a fluorescent substrate. Eachβ
cell and trachea-lung samples were analyzed in duplicate. gal activity detection threshold was 230pg. Protein content was measured withβ
a BCA protein assay kit. Additional experiments were done with lysates of gal-transduced BMC9s or Rosa26 MSCs after three cycles ofβ
freezing and thawing. Viability was ascertained by trypan blue exclusion.
Detection of  galactosidase activityβ
Tissues were fixed in 4  paraformaldehyde (at room temperature, 20min) and rinsed 3 times with PBS. Immediately after fixation,%
trachea-lungs were stained by intratracheal infusion (though a 19-gauge needle, total volume  5ml) and immersion in 5mM K4Fe(CN)6,=
5mM K3Fe3(CN)6 and 2mM MgCl in PBS containing 0.5mg/ml X-Gal (as indicated above) for 6hr, at 30 C to avoid the detection of2 °
endogenous gal activity ( ). Tissues were again washed with PBS and immediately embedded in paraffin. Tissues wereβ Weiss 1997 et al., 
identified as positive for  galactosidase activity by nuclear blue staining after X-Gal reaction. Sections (4 m thick) were stained withβ μ
nuclear fast red (Sigma).
Detection of nls-lacZ reporter gene
Total DNA from whole murine trachea-lungs was isolated for PCR analysis. Tissues were digested overnight with lysis buffer
containing proteinase K (10mg/ml, Sigma). Total DNA was extracted with phenol/chloroform/isoamyl alcohol (Sigma) method and then
precipitated in ethanol. Total DNA from 10 transduced MSCs was also extracted for PCR experiments. PCR were performed using6 
primers that specifically bind the nls sequence and the lacZ gene encoded in the nls-lacZ lentivirus vector: 5 -GTA ACA ACT CCG CCC′
CAT T -3  and 5 -GAC AGT ATC GGC CTC AGG AA -3 .′ ′ ′
Statistical analysis
Data are expressed as means  S.E.M. Statistical significance was evaluated using the analysis of variance (ANOVA) method to±
compare control and treatment groups of 3 or more. Tukey s test was subsequently used for pair-wise comparisons. A non parametric’
Mann and Whitney test was performed to compare two groups. Statistical significance was set at p<0.05.
Results
Transient epithelial airway injury induced by polidocanol intratracheal administration
Intratracheal administration of 2  PDOC induced macroscopic lung injury at 24hr with haemorrhage ( ). The major% Figs. 1b,k,n 
histological findings at 24hr were acute injury of the murine airway epithelium with focal shedding areas observed in the epithelial surface,
with only a remaining layer of basal cells or a total denudation of the basement membrane ( ). However, in some regions, theFigs. 1e,h 
luminal layer of epithelial cells was just disrupted or sloughed whereas the basal cell layer and the basement membrane remained intact
(not shown), as already described after intratracheal or intranasal administration ( and ,Driscoll 2000 et al., Southam 2002 et al., 
respectively). Inflammation was present in pulmonary parenchyma ( , arrow heads). Trachea-lung sections at 7 days after PDOCFigs. 1k,n 
administration demonstrated significant improvement of haemorrhage ( ) and of airway injury with epithelial surface againFigs. 1c,l 
covered by cilia ( ). PDOC effect did not alter significantly animal survival ( ).Figs. 1f,i Table S1 in supplementary data 
ESC and BMC9 survival in murine airway with acute epithelial airway injury
In a first set of experiments, embryonic stem cells (ESCs) and adult mesenchymal stem cells (BMC9s) from well-characterized cell
lines were intratracheally injected. ESCs and BMC9s were injected 24hr after PDOC administration, when epithelial airway injury induced
by PDOC was acute ( ). Stem cell survival was evaluated 24hr after stem cell administration. To calculate theMacPherson 2005 et al., 
survival rate, we used a quantitative method based on expression of reporter genes by transplanted cells. Stem cells werein vivo 
transfected with plasmids encoding CAT or GFP reporter genes 2hr prior to intratracheal injection. CAT-transfected stem cellsin vitro 
were then intratracheally injected, at a time where they did not yet express the foreign genes (see below). We hypothesized that only
surviving stem cells would express CAT protein in trachea-lungs 24hr after intratracheal cell injection.in vivo 
Two hours after the beginning of cell incubation with both plasmids and synthetic vectors, transfection complexes were removed and
reporter gene expression was evaluated. Neither CAT protein nor cell fluorescence was detected in stem cells using ELISA ( ) andFig. 2b 
microscopy (not shown), demonstrating that stem cells did not express CAT nor GFP protein at the time of injection. in vivo In vitro 
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reporter gene expression was also evaluated 24hr and 7 days after incubation with plasmids and synthetic vectors. As evaluated by FACS
analysis, 19.4  0.2  ESCs (n  6) and 37.0  4.4  BMC9s (n  6) expressed GFP at 24hr ( ). However, CAT and GFP± % = ± % = in vitro Fig. 2a 
were not detected at 7 days after transfection ( ), suggesting that transgene expression was transient. Using CAT ELISA quantitativeFig. 2b 
results and GFP-expressing cell rates, we calculated that CAT-expressing ESCs and CAT-expressing BMC9s contained at 24hr 0.03 ±
0.01pgCAT/cell (n  10) and 0.08  0.02pgCAT/cell (n  6), respectively. Cell values were further used to evaluate the number of = ± = in vivo 
surviving cells after intratracheal injection.
For intratracheal administration, CAT-transfected ESCs and CAT-transfected BMC9s were harvested 2hr after the beginning of
transfection and injected intratracheally. Mice were sacrificed 24hr after intratracheal administration; trachea-lungs were used toin toto 
quantify CAT protein by ELISA ( ). No CAT protein was detected in control animals or animals injected with PDOC only.Fig. 2c 
Importantly, CAT protein was detected in 61  (19/31) animals intratracheally injected with PDOC and ESCs and in 81  (17/21) animals% %
intratracheally injected with PDOC and BMC9s, suggesting that ESCs and BMC9s survived within lungs and expressed reporter genes
24hr after intratracheal injection. To estimate the number of surviving cells within the lungs at 24hr, total CAT protein quantity per animal
was divided by CAT quantity per cell . The survival rate of 10 injected stem cells was 3.69  0.86  ESCs (n  19), whereas thisin vitro 6 ± % =
survival rate was significantly less with BMC9s (0.43  0.12 , n  17, Tukey s test, p  0.02). CAT cell quantities were also used to± % = ’ =
calculate the cell detection threshold. A minimum of 10  1.2 10 ESCs and 4.3  1.1 10 BMC9s could be detected in one animal in vivo ± × 3 ± × 3 
, corresponding to 0.4 1  injected cells. These results suggest that even if the percentage of cells expressing reporter gene in vivo – % in vitro 
was low, this was still a sensitive method for detection of a small cell number.in vivo 
Influence of differentiation state and airway environment on ESC and BMC9 survival
To determine whether cell survival ability in murine injured airway was specific to stem cells, differentiated cells from various origins
(Hep3B, mOS-J and COS-7 cells) were transfected with CAT plasmids in conditions and results similar to that of ESCs andin vitro 
BMC9s (not shown). CAT-transfected differentiated cells were then intratracheally injected 2hr after the beginning of incubation with
CAT plasmid. No CAT protein was detected in any animal injected with PDOC and differentiated cells at 24hr ( ), suggesting thatFig. 2c 
only stem cells survived after intratracheal injection in injured airway. CAT-transfected ESCs and BMC9s were injected in control healthy
animals. No CAT protein was detected in any animal with healthy airway 24hr after stem cell injection ( ), suggesting that stem cellFig. 2c 
survival was favoured by airway injury.
Cell survival in the epithelial lining fluid
To evaluate whether cells expressing CAT reporter protein were present within the epithelial lining fluid or after phagocytosis by
alveolar macrophages, bronchoalveolar lavages (BALs) were performed at 24hr in conditions when phagocytosis was expectedin vivo 
maximal, e.g. when CAT ELISA results were negative: mesenchymal stem cells (BMC9s) in healthy airway and murine differentiated
cells (mOS-J) in injured airway. As further controls, BALs were also performed in control and PDOC animals and in animals
intratracheally injected with PDOC and BMC9s. No CAT protein was detected in any BAL fluid nor BAL cell sample from any animal (
), suggesting that if stem cells or differentiated cells were phagocytosed by alveolar macrophages, such phagocytosis did not alterFig. 2d 
CAT protein measurement nor cell survival detection. Importantly, in animals intratracheally injected with PDOC and BMC9s, high levels
of CAT protein were measured in trachea and lung homogenates whereas no CAT protein was detected in BAL fluid nor BAL cell
samples, suggesting that CAT-expressing cells were mostly present within the lungs and did not survive in the epithelial lining fluid (Fig.
).2d 
BMC9 location at 24hr and 7 days
Next, we investigated BMC9 location at 7 days when the airway epithelium was known to be spontaneously regenerating (
). As CAT expression using synthetic vectors was transient, we used integrative virus vectors allowing long-termMacPherson 2005 et al., 
foreign gene expression. BMC9s were transduced with a retrovirus vector encoding nls-lacZ gene. As evaluated by X-Gal staining, 57.2 ±
0.1  BMC9s expressed nuclear  galactosidase ( gal) when they were injected ( , n  6). gal activity in transduced BMC9s was% β β Fig. 3a = β
significantly increased just prior to injection as compared to endogenous gal activity in BMC9s ( , Mann and Whitney test, p β Fig. 3b =
0.02) and remained stable at 7 days (not shown). Animals were assessed for gal activity 24hr and 7 days after intratrachealβ
administration, using the 4 MUG method ( ). In contrast to previous experiments, gal-transduced BMC9s expressed nlslacZ geneFig. 3c β
at the time of intratracheal injections. Therefore, as a further control, we injected lysates of gal-transduced BMC9s, and no significantβ
increase in gal activity was observed as compared to endogenous gal activity (Tukey s test, p  0.98). In animals intratracheally injectedβ β ’ =
with PDOC and gal-transduced BMC9s, 24hr after injection gal activity significantly increased as compared to that of control animalsβ β
(Tukey s test, p  0.003) and to animals injected with PDOC and lysate of gal-transduced BMC9s (Tukey s test, p  0.004), confirming’ = β ’ =
results with CAT gene transfer. However, 7 days after stem cell injection gal activity was similar to that of control animals (Tukey s test,β ’
p  0.98) and animals injected with PDOC and lysate of gal-transduced BMC9s (Tukey s test, p  0.94), suggesting that the number of= β ’ =
surviving BMC9s in the airway epithelium decreased significantly between 24hr and 7 days.
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To locate BMC9s after intratracheal injection into injured airway, we performed X-Gal staining of trachea-lungs at 24hr and 7in toto 
days ( ). No blue staining was observed in trachea-lungs ( ) and histological sections ( ) from any control animal (Fig. 4 Fig. 4a Figs. 4b-d 
, n  3), animal injected with PDOC ( , n  3), or animal intratracheally injected with gal-transduced BMC9s only ( ,Fig. 4a = Fig. 4b = β Fig. 4c 
n  5). No cell with nuclear blue staining was observed in any animal injected with PDOC and lysate of gal-transduced BMC9s ( ,= β Fig. 4d 
n  5), suggesting that cells with nuclear blue staining expressed the nls-lacZ gene In contrast, macroscopic and microscopic= de novo. 
strong nuclear blue staining was observed in trachea and pulmonary lobes at 24hr ( , n  16) and 7 days ( , n  7) inFigs. 4e-m = Figs. 4n-p =
each animal intratracheally injected with PDOC and gal-transduced BMC9s. At 24hr, macroscopic analyses showed blue spots (<5 spots)β
in trachea from 8/16 animals ( ) and blue spots in one (15/16, ) or two pulmonary lobes (1/16, ). Blue spotsFigs. 4e,f Figs. 4g,h Figs. 4i,j 
were also observed in large bronchi from 5/16 animals ( ). Histological analyses confirmed the macroscopic result for eachFigs. 4i,j 
sample, showing -gal positive cells on histological sections where blue spots had been observed. Clusters of cells with blue nuclei wereβ
observed in the lumen of injured trachea ( ) and injured bronchi or bronchioles ( ), but not in lung parenchyma ( ).Fig. 4k Figs. 4l,m Fig. 4l 
At 7 days, blue spots were observed in 7/7 animals, in the lumen of bronchioles ( ). No blue cell was observed in trachea or inFigs. 4n-p 
pulmonary parenchyma (not shown). Clusters of blue cells were sometimes located in polyp-like structures, located in bronchioles and
large bronchi. Polyp-like structures were not observed in any animal receiving PDOC only. Further quantitative and statistical analyses
demonstrated that the development of polyp-like structures at 7 days was not due to stem cell administration but rather to a second
intratracheal administration (PBS or BMC9) 24hr after PDOC injection ( ). Histological analyses at highTable S2 in supplementary data 
magnification showed that gal-expressing cells did not have a respiratory phenotype, with no cilia at 24hr or 7 days (not shown).β
MSC survival in murine airway with acute epithelial airway injury
In a second set of experiments, to avoid cell survival linked to cell line transformation, we repeated previous experiments within vivo 
the same experimental design, using murine MSCs from primary cultures. MSC cultures were characterised according to (Dominici et al., 
) and ( ). FACS analysis demonstrated that MSCs were CD45  ( , 0.4  0.1 , n  4), CD90  (0.43 2006 Chateauvieux 2007 et al., − Fig. 5a ± % = − ±
0.2 , n  6) and CD29 , Sca-1  ( , 96.9  1.3  and 98.1  0.7  respectively, n  4) and CD106  (96  0.8 , n  4).% = + + Fig. 5a ± % ± % = + ± % =
MSCs were transiently transfected with plasmids encoding CAT or GFP reporter genes. In contrast to ESCs and BMC9s, MSCin vitro 
transfection with synthetic vectors was ineffective (not shown), therefore nucleofection was used to obtain significant gene transfer rate.
As evaluated by FACS analysis, 56.8  2.9  MSCs expressed GFP at 24hr ( , n  3), but CAT and GFP were not detected 7± % in vitro Fig. 5c =
days after nucleofection ( ), suggesting that foreign gene expression was again transient and that nucleofection could not be used forFig. 5b 
7 days experiments. CAT-transfected MSCs contained 0.35  0.02pg CAT/cell at 24hr (n  6). CAT-transfected MSCs were thenin vivo ± =
intratracheally injected 2hr after the beginning of incubation with CAT plasmid. In control mice and mice injected with PDOC only, no
CAT protein was detected at 24hr ( ). Importantly, CAT protein was detected in each animal injected with PDOC and MSCs (Fig. 5d Fig.
, n  8, Tukey s test, p<0.001), suggesting that MSCs from primary cultures survived in injured airway and expressed CAT protein after5d = ’
intratracheal administration. MSC survival rate was 5.52  1.9  (n  8), a minimum of 710  45 CAT-expressing MSCs could be detected± % = ±
in one animal , corresponding to 0.07  injected cells, confirming CAT ELISA sensitivity for experiments.in vivo % in vivo 
MSC location at 24hr and 7 days
To investigate whether MSCs could be located into the airway epithelium 7 days after cell injection, we first used MSCs in primary
cultures from gal  transgenic (Rosa26) mice, thus expressing continuously cytoplasmic gal ( ). Using the 4 MUG method (β + β Fig. 6a Fig. 6c
), gal activity was significantly increased in Rosa26 MSCs as compared to MSCs from Swiss mice ( , Mann andin vitro β Figure 6c 
Whitney test, p  0.03). Mice were assessed for gal activity 24hr and 7 days after intratracheal administration of Rosa26 MSCs or of a= β
lysate of Rosa26 MSCs ( ). As observed in previous experiments with gal-transduced BMC9s, gal activity was similar in murineFig. 6d β β
airway from control animals and animals intratracheally injected with lysates of Rosa26 MSCs (Tukey s test, p  0.68). In animals’ =
intratracheally injected with PDOC and Rosa26 MSCs, gal activity was significantly increased as compared to that of both control groupsβ
(Tukey s test, p  0.01). However, in contrast to previous experiments with gal-transduced BMC9s, no blue staining was observed in’ = β
trachea-lungs from animals injected intratracheally with PDOC and Rosa26 MSCs at 24hr, and Rosa26 MSCs could not be located on
histological slides (not shown). Finally, gal activity in murine injured airway returned to baseline at 7 days after Rosa26 MSCβ
intratracheal injection (Tukey s test, p  0.85).’ =
In a last set of experiments, as previously performed with BMC9s we overexpressed nls-lacZ gene in MSCs from wild-type Swiss
mice, to locate them at 24hr and 7 days. MSC transduction with the gal retrovirus vector remained ineffective. Therefore, MSCsin vivo β
from Swiss mice were transduced prior to intratracheal injection with a lentivirus vector encoding the nls-lacZ gene ( ).Conrad 2007 et al., 
After lentiviral transduction, 20.1  3.0  MSCs expressed gal ( , n  4). Nevertheless, no blue staining was observed in± % β Fig. 6b =
trachea-lungs from animals injected intratracheally with PDOC and gal-transduced MSCs at 7 days (not shown). Since rapid downβ
regulation of foreign gene expression under cytomegalovirus promoter has been described in lungs ( ), we concurrentlyPringle 2005 et al., 
used PCR to detect the presence of nls-lacZ gene even without gene expression. PCR experiments using primers specific to nls-lacZ gene
were performed 24hr and 7 days after gal-transduced MSC injection ( ). At 24hr, PCR was positive in trachea-lungs from eachβ Fig. 6e 
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animal injected with PDOC and gal-transduced MSCs ( , n  7), confirming that gal-transduced MSCs were present 24hr afterβ Fig. 6e = β
injection in injured airway. However, no nls-lacZ gene was detected in animals at 7 days after gal-transduced MSC injection, suggestingβ
that no gal-transduced MSCs from primary culture survived at this time once the epithelium is regenerated ( , n  6).β Fig. 6e =
Discussion
Using different and independent methods based on reporter gene transfer we demonstrated the short term survival of different types of
exogenous stem cells, including embryonic and adult mesenchymal stem cells, after intratracheal injection in murine airway presenting
acute epithelial airway injury and without total-body irradiation. In contrast to differentiated cells, 0.43 to 5.5  stem cells were capable of%
surviving within the injured lungs at 24hr. Importantly no SCs survived in healthy airway or in the epithelial lining fluid. Biochemical
staining showed that transduced MSCs were located in the lumen of conducting airway at 24hr and at 7 days. However, the amountin vivo 
of engrafted MSCs decreased dramatically with time. No primary MSCs were located within lungs at 7 days.
In our study, several gene transfer systems were used, according to our aims and to cell types. Using careful timing, non-viral vectors
were useful to allow expression of the foreign gene only after intratracheal cell injection. Gene delivery with viral vectors was used for in
studies at 7 days, but we had to use different viral vectors for transducing MSCs from cell lines and primary MSCs. Depending on thevivo 
gene transfer system and the cell type, gene transfer efficacy was variable . Studies with retrovirus vectors showed high efficacyin vitro 
and stable MSC transduction (up to 97 , ( )) whereas studies with lentivirus vectors showed variable efficacy between% Sales 2007 et al., 
murine MSCs (up to 50 , ( ; ; )) and human MSCs (up to 93 , (% Ricks 2008 et al., Santoni de Sio 2008 et al., Xu 2008 et al., % Chan et al., 
)). These data confirmed that primary murine MSCs are more difficult to transduce than human MSCs.2005 
Engraftment of exogenous stem cells into the lungs has been reported in several studies, but cell engraftment rate remainsin vivo 
controversial ( ). Our results highlight the main advantage in using ELISA and biochemical methods to detect andLoebinger 2008 et al., 
quantify a small number of administered cells in the whole organ. Although lacZ gene is widely used to locate stem cells, some reports
have shown that standard protocols for X-Gal staining can lead, especially in the lungs, both to false positive results as well as to failure to
adequately detect gal expressing cells ( ). In our study, while gal activity significantly increased after intratrachealβ Weiss 1997 et al., β
injection of MSCs from Rosa26 mice, surviving Rosa26 MSCs could not be located on histological slides, as already described inin vivo 
another report ( ). The lacZ gene coupled with a nuclear localization signal had already been used in severalMacPherson 2005 et al., 
studies from our group ( ; ) and others ( ) and was shown to allowLemarchand 1994 et al., Chapelier 1996 et al., Mastrangeli 1993 et al., 
easy detection of endogenous from exogenous gal activity. Using nls-LacZ gene, we were able to detect and locate nuclear β β
gal-expressing cells, even when gal activity in the whole lungs was not significantly different from baseline.β
We investigated whether stem cells would be capable of locating specifically on the epithelial side of airway after intratracheal
administration. BAL experiments showed that stem cells expressing reporter protein did not survive in the epithelial lining fluid. X-Gal
staining showed that stem cells were localised into conducting airway . By injecting stem cells in healthy airway, we alsoin vivo 
confirmed the major role of injured environment on the engraftment ( ). Stem cells may not engraft into healthyMacPherson 2005 et al., 
airway because of mucociliary clearance mechanism that could impede access to airway epithelium, as described for gene transferin vivo 
to the lungs ( ). We speculated that mucociliary clearance would be disrupted in polidocanol (PDOC)-treated airway and thatWeiss 2002 
the freshly denuded basement membrane may also promote specifically stem cell adherence and engraftment in the airway epithelium (
; ). In the first set of experiments, murine ESCs were intratracheally injected and a significantEngelhardt 1992 et al., Nikolova 2006 et al., 
survival cell rate was observed, although ESC transfection rate was low. This confirms the great potential of ESC pluripotency forin vitro 
regenerative medicine and in particular airway injury. Nevertheless, ESCs for cell-based therapy have met with ethical, moral and political
challenges, and with inherent risks associated with immune rejection ( ). In further experiments, we focused ourChidgey 2008 et al., 
attention on MSCs because they are already used in the clinical setting ( ). Our ELISA data indicated that MSC survivalUccelli 2008 et al., 
rate varied according to immortalized or primary cultures, probably because of the different gene transfer systems we used. Survival rates
(from 0.4  to 5.5 ) 24hr after intratracheal administration were higher than those described after intravenous administration (from 0.01% % %
to 0.1 ) and in agreement with those usually described in stem cell therapy protocols, including cardiology ( ) or% Robey 2008 et al., 
diabetology ( ) protocols, and lung injury models ( ; ; ).Bottino 2003 et al., Gupta 2007 et al., Wong 2007 et al., Wong 2009 et al., 
We hypothesized that MSC incorporation in the lungs at 7 days could be masked by a down regulation of transgene expression into the
lungs because of the common cytomegalovirus enhancer/promoter element in the virus vector constructs ( ; Alton 1999 et al., Pringle et al., 
). The negative results of PCR experiments on nls-lacZ gene at 7 days demonstrated that this was not the case. Allogeneic rejection2005 
seems unlikely to be responsible for the lack of survival of differentiated cells at 24hr since ESCs, although known to be targeted for
rejection by the immune system ( ), survived at 24hr. Nevertheless, allogeneic MSC rejection cannot be ruled out at 7Chidgey 2008 et al., 
days.
Another hypothesis to explain MSC negative results at 7 days is the spontaneous regeneration of the airway epithelium that may have
hampered MSC incorporation into epithelial airway. At 24hr, e.g. when there is a desquamation of the epithelial surface and a denuded
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basement membrane, the PDOC murine model is a good model to evaluate stem cell survival and presence in injured airway but stem cell
differentiation into airway epithelial cells is unlikely at this time. At 7 days after PDOC administration, the epithelium was spontaneously
regenerated, demonstrating that PDOC did not alter endogenous lung capability to regenerate. Therefore, the PDOC model may not be an
adequate model to evaluate stem cell capability in regenerating lung epithelium, since the endogenous repair mechanisms may impede
MSC contribution to achieve structural lung regeneration. This limitation was described in ( ) study in which theWong 2007 et al., 
naphthalene-injured airway epithelium was still undergoing rapid cell turnover and regeneration and the number of administered stem cells
also decreased with time. A more appropriate animal model to study stem cell contribution to structural lung regeneration would be a
model with chronic epithelial airway injury and a recurrent loss of the epithelial surface, due to a lack or an exhaustion of endogenous
progenitor cells. This hypothesis was evaluated in animal models with permanent retinal epithelial degeneration such as the RCS rat model
( ) and the rhodopsin knock-out mouse ( ). MSC engraftment and epithelial regenerationD Cruz 2000 ’ et al., Humphries 1997 et al., 
involving MSCs were observed in these animal models ( ; ). For lung tissue, a recent murine modelArnhold 2007 et al., Inoue 2007 et al., 
overexpressing the beta-subunit of epithelial Na  channel (ENaC ) and showing epithelial degeneration in newborn animals (+ /  + + Mall et al.,
) may be more appropriate to evaluate MSC contribution to lung regeneration.2008 
Finally, an important limitation of our study was also the lack of phenotypic characterisation of surviving cells. This characterisation
of stem cell-derived epithelial cells has been hampered by methodological problems, in the lungs as in many other organs such as the heart
( ) or the brain ( ), and remains difficult and controversial. In this regard, additional studies usingMurry 2004 et al., Castro 2002 et al., 
complex transgenic models with reporter genes under the control of lung-specific promoters will be essential.in vivo 
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Figure 1
Epithelial damage induced by intratracheal administration of polidocanol (PDOC). ( ) Trachea-lungs from ( ) control animal, ( ) animalsa c – a b 
injected with PDOC at 24hr and ( ) 7 days after PDOC administration. ( ) tracheal and ( ) bronchial sections from ( ) controlc d i – j o – d,g,j,m 
animal, ( ) animals injected with PDOC at 24hr and ( ) at 7 days. ( ) Magnification 4 . ( ) Magnification 10 . ( )e,h,k,n f,i,l,o k x d f – x j,l 
Magnification 20 . ( ) Magnification 100 . Haematoxylin counterstaining, airway epithelial damage (arrows), ciliated cells (whitex g i,m o – – x 
arrow), inflammation areas (arrow heads), haemorrhagic areas (white arrow heads). Areas marked by were magnified in the adjacentasterisks 
pictures.
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Figure 2
cell transfection with reporter genes and CAT gene expression into injured airway 24hr after intratracheal stem cellIn vitro in vivo 
administration. To follow stem cell survival , murine embryonic stem cells (ESCs) or adult mesenchymal stem cells (BMC9s) werein vivo 
transfected with plasmids encoding CAT or GFP reporter genes just prior to intratracheal administration. ( ) Representativein vitro a 
histograms of FACS analysis of GFP-expressing ESCs or BMC9s 24hr after transfection. ( ) CAT protein quantification in ESC andin vitro b 
BMC9 lysates using ELISA, 2hr, 24hr or 7 days after incubation with plasmids and synthetic vectors. ( ) CAT protein quantification in wholec 
trachea-lung homogenates using ELISA, 24hr after ESC or BMC9 intratracheal injection. Evaluated groups included animals that were
intratracheally injected with the followings: no injection (control), PDOC only (PDOC), ESCs or BMC9s only (ESC, BMC9), PDOC and
ESCs or BMC9s 24hr later (PDOC  ESC, BMC9), PDOC and differentiated cells 24hr later (PDOC  Hep3B, mOS-J, COS-7). ( ) CAT+ + d 
protein quantification in bronchoalveolar lavages and whole trachea-lung homogenates using ELISA, 24hr after BMC9 or murine
differentiated cells (mOS-J) intratracheal injection. Evaluated groups included animals that were intratracheally injected with the followings:
no injection (control), PDOC only (PDOC), BMC9s only (BMC9), PDOC and mOS-Js 24hr later (PDOC  mOS-J), PDOC and BMC9s 24hr+
later (PDOC  BMC9). Dotted line depicts control threshold.  p<0.05.+ *
Figure 3
and detection of gal activity 24hr or 7 days after gal-transduced BMC9 intratracheal administration. BMC9s wereIn vitro in vivo β β
transduced with a retrovirus vector encoding nls-lacZ gene prior to administration. ( ) Representative example of in vitro in vivo a β
gal-transduced BMC9s just prior to injection, after X-Gal staining. Magnification 20 . ( ) gal activity in BMC9s and x b In vitro β β
gal-transduced BMC9s just prior to injection. ( ) gal activity in whole trachea-lung homogenates, 24hr or 7 days after BMC9 intratrachealc β
injection. Evaluated groups included animals that were intratracheally injected with the followings: no injection (control), PDOC and lysate of
gal-transduced BMC9s (PDOC  BMC9 lysate), PDOC and gal-transduced BMC9s (PDOC  BMC9). Dotted line depicts controlβ + β +
threshold.  p<0.05.*
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Figure 4
BMC9 location 24hr and 7 days after intratracheal injection, using X-Gal staining. ( ) Trachea-lungs or histological sections at 24hr aftera d –
X-Gal staining from ( ) control animal, ( ) animal intratracheally injected with PDOC or ( ) gal-transduced BMC9s or ( ) with PDOCa b c β d 
and 24hr later gal-transduced BMC9 lysate. No blue staining was observed in any control animals. ( ) Trachea-lungs, ( ) tracheal and (β e j – k 
) bronchial sections from animals intratracheally injected with PDOC and 24hr later gal-transduced BMC9s. Animals were sacrificedl,m β
24hr after BMC9 injection and stained using X-Gal. Blue spots were observed ( ) in trachea and ( ) in pulmonary lobes. ( ) Highere,f g j – f,h,i 
power views of the area marked by in Figs. 4e,g,j, respectively. ( ) Higher power view of the area marked by in Fig. 4l. (asterisks m asterisk n–
) Trachea-lungs and histological sections from animal intratracheally injected with PDOC and gal-transduced BMC9s, sacrificed 7 daysp β
after BMC9 injection and stained using X Gal. Blue spots were observed in the lumen of bronchioles. ( ) Higher power view of the areap 
marked by in Fig. 4o. ( Magnification 4 . ( ) Magnification 10 . ( ) Magnification 20 ( ) Magnification 40 . Nuclearasterisk c,d,o) x b,l x k x. m,p x 
fast red counterstaining.
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Figure 5
cell transfection with reporter genes and CAT gene expression 24hr after intratracheal administration into injured airway ofIn vitro in vivo 
murine adult mesenchymal stem cells (MSCs) from primary cultures. ( ) MSC morphology and representative histograms of CD45, CD29a 
and Sca-1 labeling, using FACS analysis just prior to intratracheal injection. ( ) To follow MSC survival , MSCs were transfected b d – in vivo 
with plasmids encoding CAT or GFP reporter genes using nucleofection, just prior to intratracheal injection. ( ) CAT proteinin vitro b 
quantification in MSCs using ELISA, 2hr, 24hr or 7 days after incubation with plasmid and nucleofection solution. ( ) FACS analysis ofc 
GFP-expressing MSCs 24hr after incubation with GFP plasmid and nucleofection solution. ( ) CAT protein quantification in wholed 
trachea-lung homogenates using ELISA, 24hr after CAT-transduced MSC intratracheal injection. Evaluated groups included animals that
were intratracheally injected with the followings: no injection (control), PDOC only (PDOC), PDOC and 24hr later CAT-transduced MSCs
(PDOC  MSC). Dotted line depicts control threshold.+
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Figure 6
and detection of Rosa26 MSCs and gal-transduced MSCs 24hr or 7 days after administration. MSCs from wild type miceIn vitro in vivo β
were transduced with a lentivirus vector encoding nls-lacZ gene. ( ) Representative example of ( ) Rosa26 MSCs or ( ) gal-transduceda,b a b β
MSCs after X-Gal staining just prior to intratracheal injection. Magnification 20 . ( ) gal activity in MSCs and Rosa26in vitro x c In vitro β
MSCs just prior to intratracheal injection. ( ) gal activity in whole trachea-lungs homogenates, 24hr or 7 days after Rosa26 MSCd β
intratracheal administration. Evaluated groups included animals that were intratracheally injected with the followings: no injection (control),
PDOC and lysate of Rosa26 MSCs (PDOC  Rosa26 MSC lysate), PDOC and Rosa26 MSCs (PDOC  Rosa26 MSC). ( ) vivo detection+ + e In 
of the nls-lacZ gene by PCR 24hr and 7 days after intratracheal injection of gal-transduced MSCs. Dotted line depicts control threshold. β *
p<0.05.
